• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 核衣壳蛋白与 RIG-I 相互作用并抑制 RIG-Mediated IFN-β 产生。

SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN-β Production.

机构信息

State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China.

Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou 510632, China.

出版信息

Viruses. 2020 Dec 30;13(1):47. doi: 10.3390/v13010047.

DOI:10.3390/v13010047
PMID:33396605
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7823417/
Abstract

SARS-CoV-2 is highly pathogenic in humans and poses a great threat to public health worldwide. Clinical data shows a disturbed type I interferon (IFN) response during the virus infection. In this study, we discovered that the nucleocapsid (N) protein of SARS-CoV-2 plays an important role in the inhibition of interferon beta (IFN-β) production. N protein repressed IFN-β production induced by poly(I:C) or upon Sendai virus (SeV) infection. We noted that N protein also suppressed IFN-β production, induced by several signaling molecules downstream of the retinoic acid-inducible gene I (RIG-I) pathway, which is the crucial pattern recognition receptor (PRR) responsible for identifying RNA viruses. Moreover, our data demonstrated that N protein interacted with the RIG-I protein through the DExD/H domain, which has ATPase activity and plays an important role in the binding of immunostimulatory RNAs. These results suggested that SARS-CoV-2 N protein suppresses the IFN-β response through targeting the initial step, potentially the cellular PRR-RNA-recognition step in the innate immune pathway. Therefore, we propose that the SARS-CoV-2 N protein represses IFN-β production by interfering with RIG-I.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)在人类中具有高度致病性,对全球公共卫生构成巨大威胁。临床数据显示,病毒感染期间Ⅰ型干扰素(IFN)反应受到干扰。在这项研究中,我们发现 SARS-CoV-2 的核衣壳(N)蛋白在抑制干扰素β(IFN-β)产生方面发挥重要作用。N 蛋白抑制 Poly(I:C)或仙台病毒(SeV)感染诱导的 IFN-β产生。我们注意到,N 蛋白还抑制了几种信号分子诱导的 IFN-β产生,这些信号分子位于 RIG-I 途径的下游,是负责识别 RNA 病毒的关键模式识别受体(PRR)。此外,我们的数据表明,N 蛋白通过具有 ATP 酶活性且在免疫刺激性 RNA 结合中起重要作用的 DExD/H 结构域与 RIG-I 蛋白相互作用。这些结果表明,SARS-CoV-2 N 蛋白通过靶向先天免疫途径中的初始步骤,可能是细胞 PRR-RNA 识别步骤,抑制 IFN-β 反应。因此,我们提出 SARS-CoV-2 N 蛋白通过干扰 RIG-I 抑制 IFN-β 产生。

相似文献

1
SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN-β Production.SARS-CoV-2 核衣壳蛋白与 RIG-I 相互作用并抑制 RIG-Mediated IFN-β 产生。
Viruses. 2020 Dec 30;13(1):47. doi: 10.3390/v13010047.
2
Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Suppresses Type I and Type III Interferon Induction by Targeting RIG-I Signaling.中东呼吸综合征冠状病毒核衣壳蛋白通过靶向 RIG-I 信号抑制 I 型和 III 型干扰素的诱导。
J Virol. 2020 Jun 16;94(13). doi: 10.1128/JVI.00099-20.
3
SARS-CoV-2 Nucleocapsid Protein Targets RIG-I-Like Receptor Pathways to Inhibit the Induction of Interferon Response.SARS-CoV-2 核衣壳蛋白靶向 RIG-I 样受体途径抑制干扰素反应的诱导。
Cells. 2021 Mar 2;10(3):530. doi: 10.3390/cells10030530.
4
The nucleocapsid proteins of mouse hepatitis virus and severe acute respiratory syndrome coronavirus share the same IFN-β antagonizing mechanism: attenuation of PACT-mediated RIG-I/ MDA5 activation.小鼠肝炎病毒和严重急性呼吸综合征冠状病毒的核衣壳蛋白具有相同的干扰素-β拮抗机制:减弱PACT介导的RIG-I/MDA5激活。
Oncotarget. 2017 Jul 25;8(30):49655-49670. doi: 10.18632/oncotarget.17912.
5
SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity.SARS-CoV-2 N 蛋白靶向 TRIM25 介导的 RIG-I 激活以抑制先天免疫。
Viruses. 2021 Jul 23;13(8):1439. doi: 10.3390/v13081439.
6
The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination.严重急性呼吸综合征冠状病毒核衣壳蛋白通过干扰TRIM25介导的RIG-I泛素化来抑制I型干扰素的产生。
J Virol. 2017 Mar 29;91(8). doi: 10.1128/JVI.02143-16. Print 2017 Apr 15.
7
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling.严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的膜(M)蛋白通过靶向 RIG-I/MDA-5 信号通路抑制 I 型和 III 型干扰素的产生。
Signal Transduct Target Ther. 2020 Dec 28;5(1):299. doi: 10.1038/s41392-020-00438-7.
8
SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism.严重急性呼吸综合征冠状病毒核衣壳蛋白通过靶向Ⅰ型干扰素诱导途径的起始步骤来拮抗Ⅰ型干扰素反应,其C末端区域对于这种拮抗作用至关重要。
Virus Genes. 2011 Feb;42(1):37-45. doi: 10.1007/s11262-010-0544-x. Epub 2010 Oct 26.
9
West Nile Virus NS1 Antagonizes Interferon Beta Production by Targeting RIG-I and MDA5.西尼罗河病毒NS1通过靶向维甲酸诱导基因I(RIG-I)和黑色素瘤分化相关基因5(MDA5)来拮抗β干扰素的产生。
J Virol. 2017 Aug 24;91(18). doi: 10.1128/JVI.02396-16. Print 2017 Sep 15.
10
Inhibition of the RLR signaling pathway by SARS-CoV-2 ORF7b is mediated by MAVS and abrogated by ORF7b-homologous interfering peptide.SARS-CoV-2 的 ORF7b 通过 MAVS 抑制 RLR 信号通路,而 ORF7b 同源干扰肽则使其失活。
J Virol. 2024 May 14;98(5):e0157323. doi: 10.1128/jvi.01573-23. Epub 2024 Apr 4.

引用本文的文献

1
The Role of SARS-CoV-2 Nucleocapsid Protein in Host Inflammation.严重急性呼吸综合征冠状病毒2核衣壳蛋白在宿主炎症中的作用
Viruses. 2025 Jul 27;17(8):1046. doi: 10.3390/v17081046.
2
Beyond Stress Granules: G3BP1 and G3BP2 Redundantly Suppress SARS-CoV-2 Infection.超越应激颗粒:G3BP1和G3BP2对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染具有冗余抑制作用
Viruses. 2025 Jun 27;17(7):912. doi: 10.3390/v17070912.
3
Innate immunity, therapeutic targets and monoclonal antibodies in SARS-CoV-2 infection.新型冠状病毒感染中的固有免疫、治疗靶点及单克隆抗体

本文引用的文献

1
Evasion of Type I Interferon by SARS-CoV-2.SARS-CoV-2 对 I 型干扰素的逃避。
Cell Rep. 2020 Oct 6;33(1):108234. doi: 10.1016/j.celrep.2020.108234. Epub 2020 Sep 19.
2
SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)核蛋白通过抑制信号转导和转录激活因子1(STAT1)和信号转导和转录激活因子2(STAT2)的磷酸化及核转位来拮抗I型干扰素信号传导。
Cell Discov. 2020 Sep 15;6:65. doi: 10.1038/s41421-020-00208-3. eCollection 2020.
3
Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design.
PeerJ. 2025 Jun 20;13:e19462. doi: 10.7717/peerj.19462. eCollection 2025.
4
Aptamer-engaged nanotherapeutics against SARS-CoV-2.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的适配体结合纳米疗法。
Discov Nano. 2025 Apr 27;20(1):71. doi: 10.1186/s11671-025-04245-3.
5
Targeting USP22 to promote K63-linked ubiquitination and degradation of SARS-CoV-2 nucleocapsid protein.靶向USP22以促进SARS-CoV-2核衣壳蛋白的K63连接的泛素化和降解。
J Virol. 2025 May 20;99(5):e0223424. doi: 10.1128/jvi.02234-24. Epub 2025 Apr 4.
6
The R203M and D377Y mutations of the nucleocapsid protein promote SARS-CoV-2 infectivity by impairing RIG-I-mediated antiviral signaling.核衣壳蛋白的R203M和D377Y突变通过损害RIG-I介导的抗病毒信号传导来促进新型冠状病毒2的感染性。
PLoS Pathog. 2025 Jan 22;21(1):e1012886. doi: 10.1371/journal.ppat.1012886. eCollection 2025 Jan.
7
RNA Viruses, Toll-Like Receptors, and Cytokines: The Perfect Storm?RNA病毒、Toll样受体与细胞因子:完美风暴?
J Innate Immun. 2025;17(1):126-153. doi: 10.1159/000543608. Epub 2025 Jan 16.
8
Structural proteins of human coronaviruses: what makes them different?人类冠状病毒的结构蛋白:它们有何不同之处?
Front Cell Infect Microbiol. 2024 Dec 6;14:1458383. doi: 10.3389/fcimb.2024.1458383. eCollection 2024.
9
Expression of LncRNAs in anterior capsule of lens in patients with pathologic myopia complicated with cataract.病理性近视合并白内障患者晶状体前囊膜中长链非编码RNA的表达
Int Ophthalmol. 2024 Dec 16;45(1):10. doi: 10.1007/s10792-024-03366-5.
10
SARS-CoV-2 specific adaptations in N protein inhibit NF-κB activation and alter pathogenesis.N蛋白中SARS-CoV-2的特异性适应性变化抑制NF-κB激活并改变发病机制。
J Cell Biol. 2025 Jan 6;224(1). doi: 10.1083/jcb.202404131. Epub 2024 Dec 16.
SARS-CoV-2 核衣壳结构及其药物设计展望。
EMBO J. 2020 Oct 15;39(20):e105938. doi: 10.15252/embj.2020105938. Epub 2020 Sep 11.
4
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.I型、II型和III型干扰素的抗病毒活性可抵消ACE2的诱导性并限制新型冠状病毒。
mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20.
5
Liquid-liquid phase separation by SARS-CoV-2 nucleocapsid protein and RNA.严重急性呼吸综合征冠状病毒2核衣壳蛋白与RNA引发的液-液相分离
Cell Res. 2020 Dec;30(12):1143-1145. doi: 10.1038/s41422-020-00408-2. Epub 2020 Sep 8.
6
Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans.人类对轻度与重度 COVID-19 感染免疫的系统生物学评估。
Science. 2020 Sep 4;369(6508):1210-1220. doi: 10.1126/science.abc6261. Epub 2020 Aug 11.
7
Activation and evasion of type I interferon responses by SARS-CoV-2.SARS-CoV-2 激活和逃避 I 型干扰素应答。
Nat Commun. 2020 Jul 30;11(1):3810. doi: 10.1038/s41467-020-17665-9.
8
Interplay between SARS-CoV-2 and the type I interferon response.SARS-CoV-2 与 I 型干扰素应答的相互作用。
PLoS Pathog. 2020 Jul 29;16(7):e1008737. doi: 10.1371/journal.ppat.1008737. eCollection 2020 Jul.
9
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.严重 COVID-19 患者的 I 型干扰素活性和炎症反应受损。
Science. 2020 Aug 7;369(6504):718-724. doi: 10.1126/science.abc6027. Epub 2020 Jul 13.
10
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.宿主对 SARS-CoV-2 的失衡反应导致 COVID-19 的发生。
Cell. 2020 May 28;181(5):1036-1045.e9. doi: 10.1016/j.cell.2020.04.026. Epub 2020 May 15.